시장보고서
상품코드
1274677

세계의 말기 신부전(ESRD) 의약품 시장 보고서(2023년)

End Stage Renal Disease (ESRD) Drug Global Market Report 2023

발행일: | 리서치사: The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 말기 신부전(ESRD) 의약품 시장은 2022년 1,017억 3,000만 달러에서 2023년 1,158억 2,000만 달러에 달하고, 연평균 13.9% 성장할 것으로 예상됩니다. 러시아-우크라이나 전쟁은 적어도 단기적으로는 코로나19 팬데믹으로 인한 세계 경제 회복 가능성을 혼란스럽게 만들었습니다. 양국의 전쟁은 여러 국가에 대한 경제 제재, 상품 가격 상승, 공급망 혼란으로 이어져 전체 상품과 서비스에 대한 인플레이션을 유발하고 세계 많은 시장에 영향을 미쳤습니다. 말기 신부전(ESRD) 의약품 시장은 2027년까지 연평균 13.8%의 CAGR로 성장하여 1,939억 8,000만 달러에 달할 것으로 예상됩니다.

북미가 2022년 말기 신부전(ESRD) 의약품 시장에서 가장 규모가 큰 지역이 될 것으로 보입니다. 말기 신부전(ESRD) 의약품 시장 보고서는 아시아태평양, 서유럽, 중동 및 동유럽, 북미, 남미, 중동 및 아프리카를 대상으로 합니다.

비만과 당뇨병 증가는 향후 말기 신부전(ESRD) 의약품 시장의 성장을 가속할 것으로 예상됩니다. 비만은 건강상의 문제를 야기하는 비정상적이거나 과도한 지방의 축적으로 표현됩니다. 반면, 당뇨병은 췌장에서 충분한 인슐린이 생성되지 않거나 생성된 인슐린을 신체가 효율적으로 사용할 수 없을 때 발생하는 만성 질환입니다. 신장질환 환자의 경우 투석을 통해 체액과 전해질의 양, 혈압, 노폐물 배출 등을 관리함으로써 전신 건강 상태를 개선하고, 체중 감량과 혈당 조절을 개선할 수 있을 것으로 기대되고 있습니다. 예를 들어, 2022년 3월, 미국에 본부를 둔 비만 연구 및 관리 전문 국가 및 지역 단체를 대표하는 회원 조직인 World Obesity에 따르면, 2020년 세계 비만 인구는 7억 6,400만 명이며, 이 수치는 2025년 8억 9,200만 명, 2030년 10억 2,500만 명으로 증가할 것으로 예상했습니다. 10억 2,500만 명으로 증가할 것으로 예상됩니다. 또한, 벨기에에 본부를 두고 230여 개국의 당뇨병 단체를 총괄하는 국제당뇨병연맹(IDF)에 따르면, 2021년 9월 기준 약 5억 3,700만 명(20-79세)이 당뇨병을 앓고 있으며, 이 수치는 2030년 6억 4,300만 명, 2045년 7억 8,300만 명으로 늘어날 것으로 예상했습니다. 명으로 증가할 것으로 예상됩니다. 따라서 비만과 당뇨병 증가는 말기신부전증(ESRD) 치료제 시장을 견인할 것으로 보입니다.

목차

제1장 주요 요약

제2장 말기 신부전(ESRD) 의약품 시장 특징

제3장 말기 신부전(ESRD) 의약품 시장 동향과 전략

제4장 말기 신부전(ESRD) 의약품 시장 - 거시경제 시나리오

  • COVID-19가 말기 신부전(ESRD) 의약품 시장에 미치는 영향
  • 우크라이나·러시아 전쟁이 말기 신부전(ESRD) 의약품 시장에 미치는 영향
  • 고인플레이션이 말기 신부전(ESRD) 의약품 시장에 미치는 영향

제5장 말기 신부전(ESRD) 의약품 시장 규모와 성장

  • 세계의 말기 신부전(ESRD) 의약품 시장 실적, 2017-2022년
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
  • 세계의 말기 신부전(ESRD) 의약품 시장 예측, 2022-2027년, 2032년
    • 시장 성장 촉진요인
    • 시장 성장 억제요인

제6장 말기 신부전(ESRD) 의약품 시장 세분화

  • 세계의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • Calcimimetics
  • 비타민 D
  • Sterols
  • 칼륨 결합제
  • 칼슘 기반 인산염 결합제
  • 기타 제품
  • 세계의 말기 신부전(ESRD) 의약품 시장, 적응증별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 말기 신부전(ESRD) 부갑상선 기능 항진증
  • 말기 신부전(ESRD) 유발 고인혈증
  • 말기 신부전(ESRD) 유발 고칼륨혈증
  • 세계의 말기 신부전(ESRD) 의약품 시장, 유통 채널별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 병원 약국
  • 온라인 약국
  • 소매 약국
  • 세계의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 병원
  • 홈케어
  • 전문 클리닉
  • 기타 최종사용자

제7장 말기 신부전(ESRD) 의약품 시장 : 지역 및 국가별 분석

  • 세계의 말기 신부전(ESRD) 의약품 시장, 지역별, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 세계의 말기 신부전(ESRD) 의약품 시장, 국가별, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제8장 아시아태평양의 말기 신부전(ESRD) 의약품 시장

  • 아시아태평양의 말기 신부전(ESRD) 의약품 시장 개요
  • 지역 정보, COVID-19의 영향, 시장 정보, 배경 정보, 정부 이니셔티브, 규제, 규제기관, 주요 단체, 과세액, 법인세 구조, 투자, 주요 기업
  • 아시아태평양의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 아시아태평양의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제9장 중국의 말기 신부전(ESRD) 의약품 시장

  • 중국의 말기 신부전(ESRD) 의약품 시장 개요
  • 중국의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 중국의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제10장 인도의 말기 신부전(ESRD) 의약품 시장

  • 인도의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 인도의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제11장 일본의 말기 신부전(ESRD) 의약품 시장

  • 일본의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 일본의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제12장 호주의 말기 신부전(ESRD) 의약품 시장

  • 호주의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 호주의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제13장 인도네시아의 말기 신부전(ESRD) 의약품 시장

  • 인도네시아의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 인도네시아의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제14장 한국의 말기 신부전(ESRD) 의약품 시장

  • 한국의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 한국의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제15장 서유럽의 말기 신부전(ESRD) 의약품 시장

  • 서유럽의 말기 신부전(ESRD) 의약품 시장 개요
  • 서유럽의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 서유럽의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제16장 영국의 말기 신부전(ESRD) 의약품 시장

  • 영국의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 영국의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제17장 독일의 말기 신부전(ESRD) 의약품 시장

  • 독일의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 독일의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제18장 프랑스의 말기 신부전(ESRD) 의약품 시장

  • 프랑스의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 프랑스의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제19장 동유럽의 말기 신부전(ESRD) 의약품 시장

  • 동유럽의 말기 신부전(ESRD) 의약품 시장 개요
  • 동유럽의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 동유럽의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제20장 러시아의 말기 신부전(ESRD) 의약품 시장

  • 러시아의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 러시아의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제21장 북미의 말기 신부전(ESRD) 의약품 시장

  • 북미의 말기 신부전(ESRD) 의약품 시장 개요
  • 북미의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 북미의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제22장 미국의 말기 신부전(ESRD) 의약품 시장

  • 미국의 말기 신부전(ESRD) 의약품 시장 개요
  • 미국의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 미국의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제23장 남미의 말기 신부전(ESRD) 의약품 시장

  • 남미의 말기 신부전(ESRD) 의약품 시장 개요
  • 남미의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 남미의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제24장 브라질의 말기 신부전(ESRD) 의약품 시장

  • 브라질의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 브라질의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제25장 중동의 말기 신부전(ESRD) 의약품 시장

  • 중동의 말기 신부전(ESRD) 의약품 시장 개요
  • 중동의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 중동의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제26장 아프리카의 말기 신부전(ESRD) 의약품 시장

  • 아프리카의 말기 신부전(ESRD) 의약품 시장 개요
  • 아프리카의 말기 신부전(ESRD) 의약품 시장, 제품 유형별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F
  • 아프리카의 말기 신부전(ESRD) 의약품 시장, 최종사용자별 세분화, 실적 및 예측, 2017-2022, 2022-2027F, 2032F

제27장 말기 신부전(ESRD) 의약품 시장 경쟁 구도와 기업 개요

  • 말기 신부전(ESRD) 의약품 시장 경쟁 구도
  • 말기 신부전(ESRD) 의약품 시장 기업 개요
    • Pfizer Inc.
    • AstraZeneca Plc.
    • Sanofi SA
    • Astellas Pharma Inc.
    • Novartis AG

제28장 말기 신부전(ESRD) 의약품 시장의 주요 인수합병(M&A)

제29장 말기 신부전(ESRD) 의약품 시장 전망과 가능성 분석

제30장 부록

LSH 23.05.25

“End Stage Renal Disease (ESRD) Drug Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on end stage renal disease (esrd) drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for end stage renal disease (esrd) drug? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The end stage renal disease (esrd) drug market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders; Other Products
  • 2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism; End Stage Renal Disease (ESRD) Induced Hyperphosphatemia; End Stage Renal Disease (ESRD) Induced Hyperkalaemia
  • 3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Companies Mentioned: Pfizer Inc.; AstraZeneca Plc.; Sanofi SA; Astellas Pharma Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca Plc., Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, and Bristol-Myers Squibb Company.

The global end stage renal disease (ESRD) drug market is expected to grow from $101.73 billion in 2022 to $115.82 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The end stage renal disease (ESRD) drug market is expected to grow to $193.98 billion in 2027 at a CAGR of 13.8%.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person's kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).

North America was the largest region in the end stage renal disease (ESRD) drug market in 2022. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main end stage renal disease (esrd) drugs are calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics can be used to reduce PTH in kidney disease stage 5D, depending on serum calcium and phosphorus levels. The various indications include end stage renal disease (esrd) induced hyperparathyroidism, end stage renal disease (esrd) induced hyperphosphatemia, and end stage renal disease (esrd) induced hyperkalaemia. It is distributed by hospital pharmacy, online pharmacy, and retail pharmacy to be used by hospitals, homecare, specialty clinics, and other end users.

Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control. For instance, in March 2022, according to World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, there were 764 million obese people worldwide in 2020, and this figure is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in September 2021, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of over 230 national diabetes organizations, approximately 537 million individuals (20-79 years of age) were living with diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

Product innovations are a key trend in gaining popularity in the end-stage renal disease (ESRD) drug market. Major companies operating in the end-stage renal disease (ESRD) drug market are focused on developing innovative solutions to sustain in the market. For instance, in April 2022, GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the possible treatment of patients with chronic kidney disease anaemia (CKD). The new product is based on the unique nobel prize-winning science that proved how cells sense and adapt to oxygen availability.

In November 2021, Vifor Pharma, a Switzerland-based pharma company acquired Sanifit Therapeutics S.A. for an undisclosed amount. With this acquisition, Vifor Pharma expands the company's portfolio of cutting-edge assets. Sanifit Therapeutics S.A. is a Spain-based clinical-stage cardio-renal biopharmaceutical company that specializes in therapies for people with end-stage kidney diseases.

The countries covered in the end stage renal disease (ESRD) drug market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The end stage renal disease (ESRD) drug market research report is one of a series of new reports from The Business Research Company that provides end stage renal disease (ESRD) drug market statistics, including end stage renal disease (ESRD) drug industry global market size, regional shares, competitors with an end stage renal disease (ESRD) drug market share, detailed end stage renal disease (ESRD) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (ESRD) drug industry. This end stage renal disease (ESRD) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Table of Contents

1. Executive Summary

2. End Stage Renal Disease (ESRD) Drug Market Characteristics

3. End Stage Renal Disease (ESRD) Drug Market Trends And Strategies

4. End Stage Renal Disease (ESRD) Drug Market - Macro Economic Scenario

  • 4.1. COVID-19 Impact On End Stage Renal Disease (ESRD) Drug Market
  • 4.2. Ukraine-Russia War Impact On End Stage Renal Disease (ESRD) Drug Market
  • 4.3. Impact Of High Inflation On End Stage Renal Disease (ESRD) Drug Market

5. End Stage Renal Disease (ESRD) Drug Market Size And Growth

  • 5.1. Global End Stage Renal Disease (ESRD) Drug Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global End Stage Renal Disease (ESRD) Drug Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. End Stage Renal Disease (ESRD) Drug Market Segmentation

  • 6.1. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Calcimimetics
  • Vitamin D
  • Sterols
  • Potassium Binders
  • Calcium-Based Phosphate Binders
  • Other Products
  • 6.2. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
  • End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
  • End Stage Renal Disease (ESRD) Induced Hyperkalaemia
  • 6.3. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.4. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users

7. End Stage Renal Disease (ESRD) Drug Market Regional And Country Analysis

  • 7.1. Global End Stage Renal Disease (ESRD) Drug Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global End Stage Renal Disease (ESRD) Drug Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market

  • 8.1. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 8.3. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China End Stage Renal Disease (ESRD) Drug Market

  • 9.1. China End Stage Renal Disease (ESRD) Drug Market Overview
  • 9.2. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
  • 9.3. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India End Stage Renal Disease (ESRD) Drug Market

  • 10.1. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 10.2. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan End Stage Renal Disease (ESRD) Drug Market

  • 11.1. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 11.2. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia End Stage Renal Disease (ESRD) Drug Market

  • 12.1. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 12.2. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia End Stage Renal Disease (ESRD) Drug Market

  • 13.1. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 13.2. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea End Stage Renal Disease (ESRD) Drug Market

  • 14.1. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 14.2. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe End Stage Renal Disease (ESRD) Drug Market

  • 15.1. Western Europe End Stage Renal Disease (ESRD) Drug Market Overview
  • 15.2. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 15.3. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK End Stage Renal Disease (ESRD) Drug Market

  • 16.1. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 16.2. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany End Stage Renal Disease (ESRD) Drug Market

  • 17.1. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 17.2. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France End Stage Renal Disease (ESRD) Drug Market

  • 18.1. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 18.2. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe End Stage Renal Disease (ESRD) Drug Market

  • 19.1. Eastern Europe End Stage Renal Disease (ESRD) Drug Market Overview
  • 19.2. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 19.3. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia End Stage Renal Disease (ESRD) Drug Market

  • 20.1. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 20.2. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America End Stage Renal Disease (ESRD) Drug Market

  • 21.1. North America End Stage Renal Disease (ESRD) Drug Market Overview
  • 21.2. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 21.3. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA End Stage Renal Disease (ESRD) Drug Market

  • 22.1. USA End Stage Renal Disease (ESRD) Drug Market Overview
  • 22.2. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 22.3. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America End Stage Renal Disease (ESRD) Drug Market

  • 23.1. South America End Stage Renal Disease (ESRD) Drug Market Overview
  • 23.2. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 23.3. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil End Stage Renal Disease (ESRD) Drug Market

  • 24.1. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 24.2. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East End Stage Renal Disease (ESRD) Drug Market

  • 25.1. Middle East End Stage Renal Disease (ESRD) Drug Market Overview
  • 25.2. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 25.3. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa End Stage Renal Disease (ESRD) Drug Market

  • 26.1. Africa End Stage Renal Disease (ESRD) Drug Market Overview
  • 26.2. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 26.3. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape And Company Profiles

  • 27.1. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape
  • 27.2. End Stage Renal Disease (ESRD) Drug Market Company Profiles
    • 27.2.1. Pfizer Inc.
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. AstraZeneca Plc.
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Sanofi SA
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Astellas Pharma Inc.
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Novartis AG
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market

29. End Stage Renal Disease (ESRD) Drug Market Future Outlook and Potential Analysis

30. Appendix

  • 30.1. Abbreviations
  • 30.2. Currencies
  • 30.3. Historic And Forecast Inflation Rates
  • 30.4. Research Inquiries
  • 30.5. The Business Research Company
  • 30.6. Copyright And Disclaimer
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제